In 2 independent single-arm, open-label clinical studies, a single dose of either anti–IL-6 (siltuximab) or anti–IL-6R (tocilizumab) therapy was administered to individuals with established T1D. The gene discussed is IL6; the disease is type 1 diabetes mellitus.